摘要
目的 分析左西孟旦联合多巴胺治疗重症心脏瓣膜病患者的效果及对血浆内脂素的影响。方法 62例重症心脏瓣膜病患者,以随机数字表法将其分为观察组与对照组,每组31例。对照组应用多巴胺治疗,观察组在对照组的基础上加用左西孟旦治疗。比较两组患者治疗前后的血浆内脂素、心功能指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、血清炎性因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]水平及不良反应发生率。结果 治疗后,观察组患者的血浆内脂素水平(26.20±5.20)μg/L明显低于对照组的(32.67±4.20)μg/L,差异具有统计学意义(P<0.05)。治疗后,观察组患者的LVEF(53.02±4.40)%明显大于对照组的(39.23±4.23)%,LVESD(35.21±6.63)mm、LVEDD(52.20±1.36)mm明显小于对照组的(38.87±6.90)、(56.87±1.44)mm,差异具有统计学意义(P<0.05)。治疗后,观察组患者的IL-6(5.29±1.12)ng/L、hs-CRP(8.15±2.09)mg/L、TNF-α(5.79±1.10)ng/L均低于对照组的(6.79±1.16)ng/L、(11.35±2.18)mg/L、(8.35±1.13)ng/L,差异具有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 对重症心脏瓣膜病患者应用左西孟旦联合多巴胺治疗可显著改善患者的病情,且治疗安全性较高。
Objective To analyze the effect of levosimendan combined with dopamine on patients with severe valvular heart disease and its influence on plasma visfatin.Methods A total of 62 patients with severe valvular heart disease were divided into observation group and control group by random numerical table,with 31 cases in each group.The control group was treated with dopamine,and the observation group was treated with levosimendan on the basis of the control group.Both groups were compared in terms of plasma visfatin,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],serum inflammatory factors[interferin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)]levels before and after treatment,and incidence of adverse reactions.Results After treatment,the plasma visfatin level(26.20±5.20)μg/L of the observation group was significantly lower than(32.67±4.20)μg/L of the control group,and the difference was statistically significant(P<0.05).After treatment,the LVEF(53.02±4.40)%of the observation group was significantly higher than(39.23±4.23)%of the control group;the LVESD(35.21±6.63)mm and LVEDD(52.20±1.36)mm of the observation group were significantly smaller than(38.87±6.90)and(56.87±1.44)mm of the control group;the differences were all statistically significant(P<0.05).After treatment,the IL-6(5.29±1.12)ng/L,hs-CRP(8.15±2.09)mg/L,and TNF-α(5.79±1.10)ng/L in the observation group were lower than(6.79±1.16)ng/L,(11.35±2.18)mg/L,and(8.35±1.13)ng/L in the control group,and the differences were all statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Levosimendan combined with dopamine can significantly improve the condition of patients with severe valvular heart disease,and the treatment is safe.
作者
高健
GAO Jian(Zhuanghe Traditional Chinese Medicine Hospital,Zhuanghe 116400,China)
出处
《中国现代药物应用》
2022年第19期108-110,共3页
Chinese Journal of Modern Drug Application
